

Oncology Enrollment Form

Medications A-N



Noble Syracuse
 Phone: (888) 843-2040
 Fax: (888) 842-3977
 Noble Mississippi
 Phone: (866) 420-4041
 Fax: (601) 420-4040

www.noblehealthservices.com

Signature Care Program

Delivery Need By: _____ Delivery to: Patients Home Physician's Office Other

PATIENT INFORMATION		PRESCRIBER INFORMATION	
Patient Name:	<input type="checkbox"/> Female <input type="checkbox"/> Male	Prescriber Name:	
Address:		Address:	
City, State, Zip:		City, State, Zip:	
Phone:		Phone:	
Date of Birth:		Fax:	
Social Security Number:		DEA/NPI#:	

INSURANCE – PLEASE FAX COPY OF PRESCRIPTION CARD FRONT & BACK

CLINICAL INFORMATION

Diagnosis:	Has the patient been treated previously for this condition? <input type="checkbox"/> Yes <input type="checkbox"/> No
ICD-10 Code:	Medications failed:
Height: feet inches Weight: lbs.	Medications on:
Allergies:	Other notes:

PRESCRIPTION INFORMATION

Medication:	Dosage/Strength:	Directions:	Quantity:	Refills:
Afinitor® (everolimus)	<input type="checkbox"/> 2.5mg tablet <input type="checkbox"/> 7.5mg tablet <input type="checkbox"/> 5mg tablet <input type="checkbox"/> 10mg tablet	<input type="checkbox"/> Take once daily <input type="checkbox"/> Other:	# tablets	
Arzerra®	<input type="checkbox"/> 100 mg/5 ml vial <input type="checkbox"/> 1,000 mg/50 ml vial	<input type="checkbox"/>	# vials	
Avastin®	<input type="checkbox"/> 100mg/4ml (25mg/ml) vial <input type="checkbox"/> 400mg/16ml (25mg/ml) vial		# vials	
Darzalex®	<input type="checkbox"/> 400mg/20ml			
Folotyn®	<input type="checkbox"/> 20mg/1ml vial <input type="checkbox"/> 40mg/2ml vial			
Gleevec® (imatinib mesylate)	<input type="checkbox"/> 100mg tablet <input type="checkbox"/> 400mg tablet	<input type="checkbox"/> Take _____ tablets _____ time(s) a day <input type="checkbox"/> Other:		
Granix® (tbo-filgrastim)	<input type="checkbox"/> 300mcg/0.5ml syringe <input type="checkbox"/> 300mcg/ml vial <input type="checkbox"/> 480mcg/0.8ml syringe <input type="checkbox"/> 480mcg/1.6ml vial	<input type="checkbox"/> Inject _____ mcg Route: <input type="checkbox"/> IV <input type="checkbox"/> SC <input type="checkbox"/> Continuous SC Dosing directions: <input type="checkbox"/> Daily <input type="checkbox"/> Weekly <input type="checkbox"/> One time <input type="checkbox"/> Other:		
Halaven®	<input type="checkbox"/> 1mg/2ml vial			
Intron®	<input type="checkbox"/> 10mil units			
Kisqali	<input type="checkbox"/> 200mg tablets	<input type="checkbox"/> Take 600mg by mouth once daily for 21 days followed by 7 days off treatment <input type="checkbox"/> Other: _____		
Marqibo®	<input type="checkbox"/> 5mg/31ml			
Mozobil®	<input type="checkbox"/> 24mg/1.2ml vial			
Neulasta® (pegfilgrastim)	<input type="checkbox"/> 6mg/0.6ml syringe	<input type="checkbox"/> Inject _____ mcg Route: <input type="checkbox"/> IV <input type="checkbox"/> SC <input type="checkbox"/> Continuous SC Dosing directions: <input type="checkbox"/> Daily <input type="checkbox"/> Weekly <input type="checkbox"/> Other:		
Neupogen (filgrastim)	<input type="checkbox"/> 300mcg/0.5ml syringe <input type="checkbox"/> 300mcg/ml vial <input type="checkbox"/> 480mcg/0.8ml syringe <input type="checkbox"/> 480mcg/1.6ml vial	<input type="checkbox"/> Inject _____ mcg Route: <input type="checkbox"/> IV <input type="checkbox"/> SC <input type="checkbox"/> Continuous SC Dosing directions: <input type="checkbox"/> Daily <input type="checkbox"/> Weekly <input type="checkbox"/> One time <input type="checkbox"/> Other:		
Nexavar®	<input type="checkbox"/> 200mg tablet	<input type="checkbox"/> Two tablets twice daily <input type="checkbox"/> Other:		
Nplate®	<input type="checkbox"/> 250mcg vial <input type="checkbox"/> 500mcg vial			
<input type="checkbox"/> Patient is interested in patient support programs		<input type="checkbox"/> Ancillary supplies provided for administration		

Office Contact Name: _____ Preferred Phone Number & Extension: _____

Physician Signature: _____ Date: _____

E-Scribe Rx and Fax This Form

Important Notice: This communication contains information that is confidential and protected from disclosure. If the reader of this message is not the intended recipient, employee or agent responsible for delivering the message to the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this communication is strictly prohibited. If you have received this communication in error, please reply to the sender that you have received the message in error and destroy this copy.

Oncology Enrollment Form

Medications O-Z



Noble Syracuse
Phone: (888) 843-2040
Fax: (888) 842-3977
 Noble Mississippi
Phone: (866) 420-4041
Fax: (601) 420-4040

www.noblehealthservices.com

Signature Care Program

Delivery Need By: _____ Delivery to: Patients Home Physician's Office Other

PATIENT INFORMATION		PRESCRIBER INFORMATION	
Patient Name:	<input type="checkbox"/> Female <input type="checkbox"/> Male	Prescriber Name:	
Address:		Address:	
City, State, Zip:		City, State, Zip:	
Phone:		Phone:	
Date of Birth:		Fax:	
Social Security Number:		DEA/NPI#:	

INSURANCE – PLEASE FAX COPY OF PRESCRIPTION CARD FRONT & BACK CLINICAL INFORMATION

Diagnosis:	Has the patient been treated previously for this condition? <input type="checkbox"/> Yes <input type="checkbox"/> No
ICD-10 Code:	Medications failed:
Height: feet inches Weight: lbs.	Medications on:
Allergies:	Other notes:

PRESCRIPTION INFORMATION

Medication:	Dosage/Strength:	Directions:	Quantity:	Refills:
Opdivo®	<input type="checkbox"/> 40mg vial <input type="checkbox"/> 100mg vial <input type="checkbox"/> 240mg vial	<input type="checkbox"/>		
Rituxan®	<input type="checkbox"/> 100mg/10ml vial <input type="checkbox"/> 500mg/50ml vial			
Sprycel® (dasatinib)	<input type="checkbox"/> 20mg <input type="checkbox"/> 70mg <input type="checkbox"/> 40mg <input type="checkbox"/> 80mg <input type="checkbox"/> 50mg <input type="checkbox"/> 100mg	<input type="checkbox"/> Take one tablet daily <input type="checkbox"/> Other:		
Stivarga®	<input type="checkbox"/> 40mg tablet	<input type="checkbox"/> 160 mg (4 tablets) once daily on days 1 through 21 of 28 day cycle		
Supprelin®	<input type="checkbox"/> 50mg			
Sylvant®	<input type="checkbox"/> 100mg vial <input type="checkbox"/> 400mg vial			
Tasigna® (nilotinib)	<input type="checkbox"/> 150mg (28 capsules) <input type="checkbox"/> 200mg (28 capsules)	<input type="checkbox"/> Take capsule twice daily <input type="checkbox"/> Other:		
Temodar® (temozolomide)	<input type="checkbox"/> 5mg <input type="checkbox"/> 140mg <input type="checkbox"/> 20mg <input type="checkbox"/> 180mg <input type="checkbox"/> 100mg <input type="checkbox"/> 250mg	<input type="checkbox"/> Take once daily <input type="checkbox"/> Other:		
Torisel®	<input type="checkbox"/> 25mg/ml			
Vectibix®	<input type="checkbox"/> 100mg/5ml vial <input type="checkbox"/> 400mg/20ml vial			
Xeloda® (capecitabine)	<input type="checkbox"/> 150mg tablet <input type="checkbox"/> 500mg tablet	<input type="checkbox"/> Take one tablet twice daily <input type="checkbox"/> Other:		
Xgeva®	<input type="checkbox"/> 120mg/1.7			
Yervoy®	<input type="checkbox"/> 50mg/10ml vial <input type="checkbox"/> 200mg/40ml vial			
Yondelis®	<input type="checkbox"/> 1mg vial			
Zarxio® (filgrastim- sndz)	<input type="checkbox"/> 300mcg/0.5ml syringe <input type="checkbox"/> 300mcg/ml vial <input type="checkbox"/> 480mcg/0.8ml syringe <input type="checkbox"/> 480mcg/1.6ml vial	<input type="checkbox"/> Inject mcg Route: <input type="checkbox"/> IV <input type="checkbox"/> SC <input type="checkbox"/> Continuous SC Dosing directions: <input type="checkbox"/> Daily <input type="checkbox"/> Weekly <input type="checkbox"/> One time <input type="checkbox"/> Other:		
Other:				

Patient is interested in patient support programs

Ancillary supplies provided for administration

Office Contact Name: _____ Preferred Phone Number & Extension: _____

Physician Signature: _____ Date: _____

E-Scribe Rx and Fax This Form

Important Notice: This communication contains information that is confidential and protected from disclosure. If the reader of this message is not the intended recipient, employee or agent responsible for delivering the message to the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this communication is strictly prohibited. If you have received this communication in error, please reply to the sender that you have received the message in error and destroy this copy.